Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Submits Tests to NIH Genetic Testing Registry


NEW YORK (GenomeWeb) – Cancer Genetics this week said it had submitted information about three genomic and prognostic tests to the NIH's Genetic Testing Registry.

The GTR listed tests include FHACT, an HPV-associated cervical cancer test that gauges genomic abnormalities linked to disease progression; UroGenRA-Kidney, a test that can diagnose and subtype renal cell carcinoma; and MatBA, a panel for mature B-cell neoplasms, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

In a statement, Cancer Genetics CEO Panna Sharma said that the company decided to list the tests in GTR hoping to drive greater adoption of the diagnostics.

The NIH began developing the GTR four years ago aiming to develop a single, more complete repository of genetic tests. The GTR precursor, GeneTests, only listed tests for Mendelian disorders.

To date, the GTR lists approximately 400 registered labs that have submitted information on more than 17,000 tests, mostly for germline targets. In recent months, the GTR has added 128 tests that gauge somatic targets, as well as several hundred next-generation sequencing tests. And earlier this year, Genomic Health announced that healthcare providers can also find information about its Oncotype DX breast cancer recurrence test on the registry, which it touted as the first multi-analyte algorithm-based cancer diagnostic to be featured on GTR.